文献速递中毒与环境急症心脑血管急症重症综合管理与镇静镇痛

中毒性癫痫发作:特征、结局与复发

Toxicological seizures: characteristics, outcomes and recurrence.
PubMed 文献 · Clin Toxicol (Phila) · 2025-09-04
一句话结论中毒性癫痫发作最多见于曲马多、MDMA、喹硫平与可卡因,复发常见,4%患者后续诊断为癫痫,作者建议按无诱因首次癫痫发作同样严格评估随访。

该回顾性观察系列纳入2014年1月1日至2022年12月31日澳大利亚三个临床毒理学单元接诊的药物过量后癫痫发作患者,共38,493次就诊中284次就诊(275例患者)发生癫痫发作。单种促惊厥药物暴露中最常见为曲马多(9%)、3,4-亚甲二氧基甲基苯丙胺(7%)和喹硫平(7%);按各药总就诊数计算癫痫发生率最高为合成大麻素受体激动剂(21%)、曲马多(3.4%)、可卡因(2.2%)和普萘洛尔(1.9%)。22%为癫痫持续状态,随访221例中20%复发,4%新诊断癫痫。作者认为中毒性癫痫发作可能预示未来癫痫倾向,应按无诱因首次癫痫发作同样严格评估、处理与随访。

要点

  • 单种促惊厥药物暴露的202次就诊中,最常见药物为曲马多18/202(9%)、3,4-亚甲二氧基甲基苯丙胺15/202(7%)、喹硫平15/202(7%)。
  • 按各药总就诊数计算,癫痫发生率最高为合成大麻素受体激动剂9/43(21%)、曲马多18/524(3.4%)、可卡因14/516(2.2%)、普萘洛尔8/427(1.9%)。
  • 284次就诊中单次癫痫发作为169次(60%),癫痫持续状态为62次(22%);中位癫痫持续时间为1分钟(IQR 1-3分钟)。
  • 中位首次癫痫发作时间为2.5小时(IQR 1.0-7.1小时);速释制剂12小时内发作,缓释制剂24小时内发作。
  • 随访221/275例(80%)患者中,45/221(20%)复发癫痫,8例(4%)新诊断癫痫。

适用人群与场景

  • 2014年1月1日至2022年12月31日就诊于三个澳大利亚临床毒理学单元的药物过量后癫痫发作患者。
  • 共284次就诊(275例患者),中位年龄29岁(IQR 21-39岁,范围15-86岁),男性150例(55%)。
  • 29/275例(11%)患者既往有癫痫发作障碍记录。

红旗征与不能漏的情况

  • 药物过量后癫痫发作,82次就诊(30%)摄入超过一种促惊厥药物。
  • 合成大麻素受体激动剂暴露后癫痫发生率为9/43(21%),为各药中最高。
  • 62次就诊(22%)出现癫痫持续状态。
  • 速释制剂癫痫发作在12小时内出现,缓释制剂在24小时内出现。

研究设计与关键结果

  • 研究类型为回顾性观察系列,来自三个澳大利亚临床毒理学单元,9年间共38,493次就诊,其中284次就诊(275例患者)发生癫痫发作。
  • 202次单种促惊厥药物暴露中,最常见药物为曲马多18/202(9%)、3,4-亚甲二氧基甲基苯丙胺15/202(7%)、喹硫平15/202(7%)。
  • 按各药总就诊数计算癫痫发生率:合成大麻素受体激动剂9/43(21%)、曲马多18/524(3.4%)、可卡因14/516(2.2%)、普萘洛尔8/427(1.9%)。
  • 单次癫痫发作169例(60%),癫痫持续状态62例(22%);中位癫痫持续时间1分钟(IQR 1-3分钟);中位首次发作时间2.5小时(IQR 1.0-7.1小时)。
  • 随访221/275例(80%)患者,癫痫复发45/221(20%),8例(4%)新诊断癫痫。

证据类型、等级与局限

  • 证据类型:回顾性观察系列。
  • 作者结论认为中毒性癫痫发作可能预示未来癫痫倾向,支持按无诱因首次癫痫发作同样严格评估、处理与随访。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为中毒性癫痫发作应像无诱因首次癫痫发作一样严格评估、处理和随访。
  • 作者认为中毒性癫痫发作可能预示未来癫痫发作倾向和癫痫。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Seizures are a marker of severe toxicity following overdose. Research characterising toxicological seizures is limited. We aim to study toxicological seizures, causative agents, and recurrence.

METHODS: This is a retrospective observational series of patients with seizure after drug overdose, presenting to three Australian clinical toxicology units between 1 January 2014 and 31 December 2022. Patients were identified from the database of each unit, and data were supplemented by the patient's medical record. Follow-up data were extracted in June 2024.

RESULTS: Over the nine-year period, there were 38,493 presentations to the three toxicology units. A seizure occurred in 284 presentations (275 patients). The median age was 29 years (IQR: 21-39 years; range: 15-86 years), and there were 150 males (55%). A previous seizure disorder was documented in 29/275 (11%) patients. In 82 (30%) presentations, more than one proconvulsant drug was taken. In 202 single proconvulsant exposures, the most common agents were tramadol (18/202, 9%), 3,4-methylenedioxymetamfetamine (15/202, 7%), and quetiapine (15/202, 7%). The highest seizure rate, considering total presentations for each agent, was for synthetic cannabinoid receptor agonists (9/43, 21%), tramadol (18/524, 3.4%), cocaine (14/516, 2.2%), and propranolol (8/427, 1.9%). A single seizure occurred in 169 (60%) cases, while status epilepticus occurred in 62 (22%). The median seizure duration was 1 min (IQR:1-3 min). The median time to the first seizure was 2.5 h (IQR: 1.0-7.1 h). Seizures occurred within 12 h for immediate-release preparations and within 24 h for slow-release preparations. Follow-up occurred in 221/275 (80%) patients. Seizure recurrence occurred in 45/221 (20%) patients. In eight patients (4%), a new diagnosis of epilepsy was established.

DISCUSSION: Both seizure recurrence and a subsequent diagnosis of epilepsy occurred more frequently than expected. A toxicological seizure may herald a propensity for future seizures and epilepsy.

CONCLUSIONS: In this series, toxicological seizures were most common after tramadol, 3,4-methylenedioxymetamfetamine, quetiapine and cocaine. Seizure recurrence was common, with 4% of patients later diagnosed with epilepsy, supporting toxicological seizures being investigated, managed and followed up as rigorously as unprovoked first seizures.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. McCulloch K, Berling I, Chiew AL, et al. Toxicological seizures: characteristics, outcomes and recurrence. Clin Toxicol (Phila). 2025. PMID: 40905686. doi:10.1080/15563650.2025.2512827

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。